| Company/Division name | Biosimilar Solutions |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2021 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 200 |
| Country(ies) from which reshored: | United States |
| City reshored to: | Aguadilla |
| State(s) reshored to: | PR |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | recombinant biotechnologies, COVID-19 vaccine |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Infrastructure, Raw Materials Cost, Skilled workforce availability/training, Other, Covid-19 |
